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Introduction and Commentary: Paving the Way for
Biosimilars in Oncology, Part 3Clinical and Economic Impact of Oncology BiosimilarsFigure. Paving the Way for Biosimilars. This three-part
series is focused on informing physicians about the latest
developments that affect the integration of biosimilars
into oncology practices.I
n February 2012, the US Food and Drug Admin-
istration issued draft guidance documents for
industry on biosimilars.1 A biosimilar is a biolo-
gic drug that is highly similar to an approved
reference biologic (ie, the two drugs usually have
the same primary structure, among other molecular
similarities).1 This is notwithstanding any minor
differences and/or clinically inactive components
with no demonstrated clinically meaningful differ-
ences between the biosimilar and its reference
biologic product in terms of safety, purity, and
potency.1 Biosimilars are not generics, which are
produced by standard chemical synthesis, and their
development is driven by considerations unique to
living systems.2 They have the potential to facilitate
patient access to cost-effective alternatives3 and may
foster a competitive environment for biologic devel-
opment and commercialization.4
Since the first biosimilars reached the global
markets, their use has been steadily increasing.5 This
three-part series informs healthcare providers about
biosimilars, from practical perspectives associated
with development and approval, to safety and clin-
ical trials considerations (Figure). Building on infor-
mation provided in the first two supplements of the
series, the authors of the third supplement article,
Integrating Oncology Biosimilars Into Clinical Practice,
highlight clinical practice issues that oncologists
may consider as biosimilars become available. How
will treatment guideline committees such as those of
the National Comprehensive Cancer Network inte-
grate and prioritize the use of biosimilars? Will
biosimilars have uniquely identifiable names? What
will be the extent of similarity with respect to
the reference product? Much will depend on
the concept of “how similar is similar enough?”0093-7754
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Much of the rationale for the use of biosimilars is
directed toward improving access to biological
therapies in a cost-efficient manner.6 Sales of oncol-
ogy drugs in the United States rose fourfold from
1998 to 2008, with most of the drugs being high-cost
biologics.7 The authors of Pharmacoeconomics of Cancer
Therapies: Considerations With the Introduction of Biosi-
milars review how evidence derived from pharma-
coeconomic evaluations can inform the healthcare
community as it seeks to provide care that is safe,
cost-effective, and supportive of additional health
improvements. This final article in the series will
highlight factors affecting the impact of biosimilars
on healthcare costs and systems.SUMMARY AND OUTLOOK
Biosimilars have the potential to sustainably
improve access and manage healthcare cost. The in-
troduction of biosimilars into the US market is near,
and much can be learned from global experiences
with biosimilars. Education and partnership among
physicians, nurses, pharmacists, and other members
of the global healthcare community may help extend
the availability of effective medications to larger
numbers of patients.-S2 S1
Key Points From Paving the Way for Biosimilars in Oncology Supplement Series
● Biosimilars are biologics that are reverse-engineered from the innovator after loss of exclusivity and
intended to have a highly similar effect. Biosimilars are not generics8,9
● Biosimilars represent a potential opportunity to lower the cost of treatment and increase patient
accessibility to biologics10
● The product is the process: the structure, function, and quality of a biosimilar are the direct result of
the manufacturing process by which it was produced11
● With biosimilars, regulatory approval is tailored scientiﬁcally and based upon an extensive
comparability exercise12
● Safety monitoring that is systematic and ongoing is necessary for all approved drugs, including
biosimilars12
● The regulatory framework for biosimilars is evolving, with authorization via a totality of evidence
approach used on a product-by-product basis13
● Pharmacoeconomics of biosimilars may be affected by manufacturing and development costs,
comparative safety and efﬁcacy to ﬁrst- and second-generation biologics, safety monitoring costs, and
institutional pricing policies14
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